Logo Comprehensive Cancer Center Niedersachsen
Comprehensive Cancer Center Niedersachsen / CCC-N > About us > Principal Investigators > Schambach

Prof. Dr. Axel Schambach

Axel Schambach is a Principal Investigator in SP7 and a member of the Selection Committee.

His research focus lies on disease modeling and tailored therapy as well as gene and cell therapy in molecular medicine, especially molecular oncology.

Professor Schambach has served in a wide variety of roles in the research system, including as president of the German Society for Gene Therapy (since 2023), EU-/ERC-Representative for the MHH Senate (since 2021), Vice Chairman of the PhD Program Molecular Medicine (since 2020), and member of the Research Committee of the MHH (since 2020).

Curriculum Vitae

Year Position
Since 2017 Director, Institute of Experimental Hematology, MHH
2013-2017 Acting Director, Institute of Experimental Hematology, MHH
2013-now W3 Professor for Genetic Modification of Somatic Cells, MHH
2012-now Adjunct Faculty and Lecturer, Division of Hematology / Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, USA
2012-2019 Group Leader RGs Regenerative Gene Therapy und Enhanced & Synthetic Cells for Regeneration, REBIRTH Cluster of Excellence, MHH
2009-2014 Junior Group Leader, JRG Modern Applications in Biotechnology, Gene therapy, supported by DAAD and BMBF
2007-2012 Junior Group Leader, JRG Hematopoietic Cell Therapy, REBIRTH Cluster of Excellence, MHH
2005 PhD (“summa cum laude”), Hannover Medical School (Supervisor: Prof. Christopher Baum)
2002-2006 Scientist, Experimental Cell Therapy / Institute of Experimental Hematology, MHH
2003 Dr. med. (“summa cum laude”), Hamburg University (Supervisors: Prof. Hans-Georg Kräusslich, Prof. Christopher Baum)
2002-2003 Resident doctor, Children’s Hospital, MHH
1995-2001 Studies of Human Medicine, Hamburg University